Inflammatory conditions as they occur during periodontal disease often result in decreased alveolar bone levels and a loss of connective tissue homeostasis. Here we have focused on the effect of microRNA-138 (miR-138) as a potential regulator of periodontal stem cells as they affect homeostasis during inflammatory conditions. Our data indicate that miR-138 was significantly upregulated in our periodontal disease animal model. Interaction of miR-138 with a predicted targeting site on the osteocalcin (OC) promoter resulted in a 3.7-fold reduction of luciferase activity in promoter assays compared with controls; and miR-138 overexpression in periodontal progenitors significantly inhibited OC (3.4-fold), Runx2 (2.8-fold), and collagen I (2.6-fold). Moreover, treatment with inflammatory modulators such as interleukin (IL)-6 and lipopolysaccharide (LPS) resulted in a significant 2.2-fold (IL-6) or 1.9-fold (LPS) increase in miR-138 expression, while OC and Runx2 expression was significantly decreased as a result of treatment with each inflammatory mediator. Further defining the role of miR-138 in the OC-mediated control of mineralization, we demonstrated that the LPS-induced downregulation of OC expression was partially reversed after miR-138 knockdown. LPS, miR-138 mimic, and OC small interfering RNA inhibited osteoblast differentiation marker alkaline phosphatase activity, while miR-138 inhibitor and OC protein addition enhanced alkaline phosphatase activity. Supporting the role of OC as an essential modulator of osteoblast differentiation, knockdown of miR-138 or addition of OC protein partially rescued alkaline phosphatase activity in periodontal ligament (PDL) cells subjected to LPS treatment. Our data establish miR-138 inhibitor as a potential therapeutic agent for the prevention of the bone loss associated with advanced periodontal disease.

Preliminary experiments leading to the development of an optical fiber acoustic emission sensor is described. The objective was to develop a single sensor for simultaneous detection of acoustic emission events, from many locations within a large structure. The optical fiber sensor can be adhered to the surface of structural materials, i.e. steel or concrete. There are no individual sensor arrays or components built into the fiber. This characteristic provides simplicity and renders the system practical for applications in bridge structures. Alternatively, the optical fiber could be embedded in new concrete construction. Acoustic emissions from micro-cracks or defects from various locations in the stmcture create stress wave perturbations in the optical fiber that are detected by a portable interferometer. Time-domain measurements are instantaneous, in real-time, and the entire structure is interrogated through a one-time operation. The time domain signal acquired from the optical fiber discerns the number and locations of damage zones i.e., weld cracks, bolt-hole cracks, corrosion activity, or brittle fracture of fibers in composite materials.

Condition Monitoring of civil structures is best accomplished by way of distributed sensors. Sensors capable of making distributed measurements allow for monitoring the entire structure. Optical fiber sensors are especially very attractive for this purpose, since they are geometrically versatile and they can be readily integrated within various types of structures and materials. The research presented here describes the development of a new optical fiber sensor system for measurement of structural strains based on white light interferometry. Individual sensors are linked in series and an optical switch provides for multiplexing of strain signals from various locations in the structure. Bragg grating type fiber optic sensors as well as strain gauges were employed for comparison and verification of strain signals as measured by the new system. The system provides capability for distributed sensing of strains in large structures.

Purpose/Objective(s): Leptomeningeal metastasis (LM) is associated with limited survival and treatment options for patients with solid tumor malignancies. While photon involved-field radiotherapy (IFRT) is effective for local palliation, it lacks durability. Craniospinal irradiation (CSI), in contrast, treats the entire central nervous system (CNS) compartment, thus potentially improving disease control. We previously reported the safety and tolerability of proton CSI (pCSI) in a completed phase IB study, and we are now reporting the mature survival outcomes of these patients. Materials/Methods: We enrolled 24 patients with solid tumor LM to receive hypofractionated pCSI of 30 Gy (RBE) in 10 fractions in this phase I prospective trial between June 2018 and May 2019 (NCT03520504). The primary endpoint is dose-liming toxicity (DLT) within 1 month of treatment. Secondary endpoints, including time to CNS progression (CNS TTP), CNS progression-free survival (PFS), and overall survival (OS), were assessed using Kaplan-Meier analysis with median survival estimates and 95% confidence intervals (CI) reported. Correlations between cerebrospinal fluid (CSF) circulating tumor cells (CTCs) and survival outcomes were evaluated using Kaplan-Meier analysis. An optimal cutoff for CTCs was determined through maximally selected rank statistics using CNS PFS.Results: Of the 24 patients enrolled, 3 did not complete treatment due to systemic disease progression and were excluded from this analysis. The majority of patients had metastatic lung (52%) and breast (33%) malignancies. The median age was 52 years (range 30-67 years) and the median Karnofsky performance status was 70 (range 60-90). The majority of patients had LM that progressed on other therapies prior to enrollment (57% vs. 43% of patients with newly diagnosed LM), and all patients with molecularly driven disease had CNS progression on small-molecule tyrosine kinase inhibitors prior to enrollment. Only 1 patient was censored at 24 months of follow-up, while 20 patients were followed until death with a median OS of 9 months (95% CI 6-22 months). The median CNS TTP was 8 months (95% CI 7-18 months), with 5 (24%) patients with durable CNS control for > 12 months after pCSI. The median CNS PFS was 7 months (95% CI 5-13 months). In the 18 patients with CSF CTCs evaluation at baseline, having a pre-pCSI CSF CTCs < 41/3mL was associated with improved CNS TTP (19 vs. 8 months, P < 0.01), CNS PFS (18 vs. 6 months, P < 0.01), and a trend toward improved OS (21 vs. 8 months, P = 0.06). Conclusion:We reported that pCSI is a safe treatment for patients with solid tumor LM. In this analysis, we demonstrated durable disease control and prolonged survival in some patients. Lower CSF CTCs at baseline, a potential biomarker of response, was associated with improved survival outcomes. An ongoing randomized phase II trial will determine the efficacy of pCSI compared to photon IFRT in patients with solid tumor LM.

No abstract